Risk factors for cholangiocarcinoma
- PMID: 21488076
- PMCID: PMC3125451
- DOI: 10.1002/hep.24351
Risk factors for cholangiocarcinoma
Abstract
Cholangiocarcinoma (CC) is the second most common primary hepatic malignancy after hepatocellular cancer. CC accounts for approximately 10%-25% of all hepatobiliary malignancies. There are considerable geographic and demographic variations in the incidence of CC. There are several established risk factors for CC, including parasitic infections, primary sclerosing cholangitis, biliary-duct cysts, hepatolithiasis, and toxins. Other less-established potential risk factors include inflammatory bowel disease, hepatitis C virus, hepatitis B virus, cirrhosis, diabetes, obesity, alcohol drinking, tobacco smoking, and host genetic polymorphisms. In studies where the distinction between intra- and extrahepatic CC was used, some potential risk factors seem to have a differential effect on CC, depending on the site. Therefore, the consistent use of a more refined classification would allow a better understanding of risk factors for CC.
Copyright © 2011 American Association for the Study of Liver Diseases.
Similar articles
-
Risk factors for cholangiocarcinoma.Eur J Gastroenterol Hepatol. 2007 Aug;19(8):615-7. doi: 10.1097/MEG.0b013e328224b935. Eur J Gastroenterol Hepatol. 2007. PMID: 17625428 Review.
-
Epidemiology of cholangiocarcinoma.Best Pract Res Clin Gastroenterol. 2015 Apr;29(2):221-32. doi: 10.1016/j.bpg.2015.02.003. Epub 2015 Feb 16. Best Pract Res Clin Gastroenterol. 2015. PMID: 25966423 Review.
-
Primary sclerosing cholangitis and cholangiocarcinoma: pathogenesis and modes of diagnostics.Dig Dis. 2013;31(1):118-25. doi: 10.1159/000347206. Epub 2013 Jun 17. Dig Dis. 2013. PMID: 23797133 Review.
-
The epidemiology of cholangiocarcinoma.Semin Liver Dis. 2004 May;24(2):115-25. doi: 10.1055/s-2004-828889. Semin Liver Dis. 2004. PMID: 15192785 Review.
-
Clinical presentation, risk factors and staging systems of cholangiocarcinoma.Best Pract Res Clin Gastroenterol. 2015 Apr;29(2):245-52. doi: 10.1016/j.bpg.2015.02.001. Epub 2015 Feb 14. Best Pract Res Clin Gastroenterol. 2015. PMID: 25966425 Review.
Cited by
-
Liquid biopsy in cholangiocarcinoma: Current status and future perspectives.World J Gastrointest Oncol. 2021 May 15;13(5):332-350. doi: 10.4251/wjgo.v13.i5.332. World J Gastrointest Oncol. 2021. PMID: 34040697 Free PMC article. Review.
-
Stereotactic radiotherapy for intrahepatic cholangiocarcinoma.World J Gastrointest Oncol. 2022 Aug 15;14(8):1478-1489. doi: 10.4251/wjgo.v14.i8.1478. World J Gastrointest Oncol. 2022. PMID: 36160742 Free PMC article. Review.
-
Comparative proteomic profiling of human bile reveals SSP411 as a novel biomarker of cholangiocarcinoma.PLoS One. 2012;7(10):e47476. doi: 10.1371/journal.pone.0047476. Epub 2012 Oct 31. PLoS One. 2012. PMID: 23118872 Free PMC article.
-
Multiple cells of origin in cholangiocarcinoma underlie biological, epidemiological and clinical heterogeneity.World J Gastrointest Oncol. 2012 May 15;4(5):94-102. doi: 10.4251/wjgo.v4.i5.94. World J Gastrointest Oncol. 2012. PMID: 22645632 Free PMC article.
-
Bile duct carcinoma recurrence in the papillary region in a long-term survivor of hilar cholangiocarcinoma: a case report.J Med Case Rep. 2016 Oct 26;10(1):299. doi: 10.1186/s13256-016-1073-6. J Med Case Rep. 2016. PMID: 27784337 Free PMC article.
References
-
- Gatto M, Bragazzi MC, Semeraro R, Napoli C, Gentile R, Torrice A, et al. Cholangiocarcinoma: update and future perspectives. Dig Liver Dis. 2010 Apr;42(4):253–260. - PubMed
-
- Patel T. Cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol. 2006 Jan;3(1):33–42. - PubMed
-
- Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis. 2004 May;24(2):115–125. - PubMed
-
- Blechacz BR, Gores GJ. Cholangiocarcinoma. Clin Liver Dis. 2008 Feb;12(1):131–50. ix. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical